Vericel (VCEL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.04
- Estimate
- -$0.03
- Surprise
- +250.0%
- Revenue (period 2026-06-30)
- $77.5M
- Score today
- 6.2/10
Revenue source: xbrl.
How the report landed
Vericel (VCEL) beat the -$0.03 estimate with adjusted EPS of $0.04 — a large 250.0% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates VCEL Hold at 6.2/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +250.0% surprise compares with a +285.3% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: Matricel GmbH
- Concentration risk — Supplier: MediWound
- Earnings in 6 days (event risk)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $41.09
- Price target
- $51.95
- Stop
- $38.21
- Upside to target
- +26.4%
- Reward-to-risk
- 3.7:1
The stock trades at 87.4× trailing but 48.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
VCEL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.10B
- P/E (fwd)
- 48.6
- P/E (ttm)
- 87.4
- 52-week range
- $28.95–$49.32
- Off 52-week high
- 16.7%
- RSI (14)
- 56
- Volume vs avg
- 1.23×
- Score today
- 6.2/10